Missouri lawmakers have approved legislation aimed at expanding therapeutic access to and research on psychedelics such as psilocybin and ibogaine for adults and military veterans.
On Wednesday, members of the House Emerging Issues Committee passed two psychedelics proposals—combining two psilocybin- and two ibogaine-focused bills from Reps. Matthew Overcast (R) and Rep. Richard West (R)—that would take a series of steps to fund psychedelics studies, prepare for federal approval of novel therapeutics and create regulated psilocybin programs through which the substance could be administered to eligible patients.
The ibogaine measures as introduced by both lawmakers were identical, but there were certain differences in the psilocybin bills that were merged. The final text of the merged legislation hasn’t been released yet, however, so it’s currently unclear what made it in the deal.
Here’s an overview of all four of the Missouri psychedelics bills that were taken up in committee:
HB 2817 (Overcast) and HB 2961 (West) As introduced, the Veterans Mental Health Innovation Act—identical versions of which were filed by both Overcast and West—would create a state fund to support federal Food and Drug Administration- (FDA) approved clinical trials exploring the therapeutic potential of ibogaine for opioid misuse disorder and other
Read full article on Marijuana Moment
